Medicine Recommendations

LSCMMG

Red

BwD

Red

Red

Red

Red

Red

Red

Red

Red

Hydroxycarbamide

Date Posted: 01 - Jul - 2018

BNF chapter: Immune system and Malignant Disease

Expand/Collapse

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Red

Red

Red

Red

Red

Red

Red

Red

Red

Hydroxycarbamide

Date Posted: 01 - Jul - 2018

BNF chapter: Immune system and Malignant Disease

Expand/Collapse

Psoriasis

Red

Red

Red

Red

Red

Red

Red

Red

Red

Hydroxycarbamide

Date Posted: 01 - Jul - 2018

BNF chapter: Immune system and Malignant Disease

Expand/Collapse

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Hydroxychloroquine Sulfate

Date Posted: 01 - Oct - 2014

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Green

Pending

Pending

Green

Pending

Pending

Green

Green

Pending

Hyoscine Hydrobromide

Date Posted: 01 - Jun - 2015

BNF chapter: Central nervous system

Expand/Collapse

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Amber 0

Amber 0

Pending

Amber 0

Amber 0

Red

Amber 0

Amber 0

Pending

Ibandronic acid injection

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Treatment of post menopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Ibandronic acid - oral

Date Posted: 01 - Nov - 2013

BNF chapter: Endocrine system

Expand/Collapse

Postmenopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Green

Green

Green

Green

Green

Green

Green

Green

Green

Ibandronic acid

Date Posted: 01 - Sep - 2017

BNF chapter: Endocrine system

Expand/Collapse

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Green

Pending

Green

Pending

Pending

Green

Pending

Pending

Pending

Ibuprofen

Date Posted: 01 - Jan - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Green

Pending

Green

Pending

Pending

Green

Pending

Pending

Pending

Ibuprofen

Date Posted: 01 - Jan - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Pain

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Grey

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Idarucizumab

Date Posted: 16 - Nov - 2020

BNF chapter: Cardiovascular system

Expand/Collapse

Reversal of the anticoagulant effect of Dabigatran

Red

Red

Red

Red

Red

Red

Red

Red

Red

Iloprost (IV)

Date Posted: 01 - May - 2013

BNF chapter: Cardiovascular system

Expand/Collapse

Raynauds

Green

Pending

Pending

Green

Pending

Pending

Green

Green

Pending

Imipramine

Date Posted: 01 - Mar - 2015

BNF chapter: Central nervous system

Expand/Collapse

Depressive illness

Black

Pending

Pending

Black

Pending

Red

Black

Black

Black

Imiquimod Cream 3.75%

Date Posted: 01 - Sep - 2013

BNF chapter: Skin

Expand/Collapse

Treatment of Actinic Keratosis

Red

Red

Red

Red

Red

Red

Red

Red

Amber 0

Imiquimod Cream 5%

Date Posted: 01 - Jul - 2018

BNF chapter: Skin

Expand/Collapse

Treatment of small superficial basal-cell carcinomas in adults

Red

Red

Red

Red

Red

Red

Red

Red

Red

Infliximab

Date Posted: 01 - Feb - 2016

BNF chapter: Musculoskeletal system

Expand/Collapse

Rheumatoid arthritis (LSCMMG pathway)

Red

Red

Red

Red

Red

Red

Red

Red

Red

Infliximab

Date Posted: 01 - May - 2013

BNF chapter: Musculoskeletal system

Expand/Collapse

Psoriatic arthritis (NICE TA199)

NICE TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Red

Pending

Red

Red

Pending

Red

Red

Red

Pending

Infliximab

Date Posted: 01 - Nov - 2014

BNF chapter: Musculoskeletal system

Expand/Collapse

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .

Red

Pending

Red

Red

Pending

Red

Red

Red

Red

Infliximab

Date Posted: 01 - May - 2016

BNF chapter: Gastro-intestinal system

Expand/Collapse

Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.

Red

Pending

Red

Red

Pending

Red

Red

Red

Pending

Infliximab

Date Posted: 01 - Jun - 2015

BNF chapter: Musculoskeletal system

Expand/Collapse

Breadcrumb

Medicine Recommendations

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of post menopausal osteoporosis

Postmenopausal osteoporosis

Osteoporosis (NICE TA464)

Acute Gout (as per LSCMMG Guidelines)

Pain

Raynauds

Depressive illness

Treatment of Actinic Keratosis

Treatment of small superficial basal-cell carcinomas in adults

Psoriatic arthritis (NICE TA199)

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .

Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.

Juvenile Idiopathic Arthritis (JIA) in Adult Patients